Pulmonary Sarcoidosis Clinical Trial
Official title:
Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis
Verified date | February 2024 |
Source | Istanbul University - Cerrahpasa (IUC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pulmonary rehabilitation is a key element in the management of people with chronic respiratory disease. A properly followed supervised physical training program in sarcoidosis is safe and has no absolute contraindications. Fatigue can also be associated with sarcoidosis for different reasons. Individualized rehabilitation training can improve the symptoms of patients with sarcoidosis. There is no study in the literature investigating the effectiveness of one-legged exercises that reduce peripheral muscle use, in patients with sarcoidosis. In our study, these two exercise methods will be compared by applying one-legged exercise training and two-legged exercise training. The effect of one-legged exercise training on exercise capacity and fatigue in sarcoidosis patients will be examined. The primary aim of our study is to compare the effects of one-legged exercise training, which is a current exercise approach, and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. The secondary aim is to examine the effect of this exercise training on peripheral muscle strength and quality of life parameters.
Status | Active, not recruiting |
Enrollment | 26 |
Est. completion date | August 1, 2024 |
Est. primary completion date | April 21, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: - According to chest X-ray findings, the severity of the disease is to be stage 2,3,4 - Reaching a score of = 22 on the fatigue assessment scale - To be clinically stable. - No change in medical treatment. Exclusion Criteria: - Having an orthopedic, neurological, cardiac, or metabolic condition that may prevent participation and continuation of the exercise program throughout the study. |
Country | Name | City | State |
---|---|---|---|
Turkey | Istanbul University Cerrahpasa | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Istanbul University - Cerrahpasa (IUC) |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Dyspnoea | Change of Medical Research Council Scale results from baseline to 8 weeks. The Medical Research Council Scale (MRCS) is a five-item scale based on various physical activities that produce dyspnea. Here, patients are asked to mark the level of activity that causes dyspnea in themselves. On the scale, 0 describes the best 4 dyspnea and the worst. | 8 weeks | |
Other | Muscle strength | A hand-held dynamometer will be used to evaluate muscle strength. Muscle strength will be evaluated in the following muscles, each measurement will be made three times and the average will be taken.
M. Quadriceps Femoris, M. Tibialis Anterior, and M. Gastrosoleus |
8 weeks | |
Other | Health Related Quality of Life | Change of Saint George Respiratory Questionnaire Results from baseline to 8 weeks.It is a self-answered questionnaire consisting of three categories, evaluating the symptoms, activities and effects of patients on daily life. It was developed in order to determine the severity of the disease as more comprehensive and sensitive. Symptoms examined; cough, sputum, wheezing and shortness of breath. Physical functions, housework and hobbies are questioned to determine activity status. The survey consists of 76 questions and is completed in 20 minutes. 0 indicates excellent health and 100 indicates worst healt | 8 weeks | |
Other | The Leicester Cough Questionnaire (LCQ) | Change of The Leicester Cough Questionnaire (LCQ) Results from baseline to 8 weeks. The Leicester Cough Questionnaire (LCQ) is a HRQoL questionnaire validated for assessing chronic cough. It is a 19-item, self-completed questionnaire exploring the impact of cough severity across three domains: physical (eight items), psychological (seven items) and social (four items). The total severity score ranges from 3 to 21, with a lower score indicating greater impairment of health status due to cough. | 8 weeks | |
Primary | Change of Six-Minute Walking Test Distance from baseline to 8 weeks | The distance covered in meters in a straight corridor of 30 meters will be recorded as fast as possible but without running for 6 minutes. The distance that normal individuals should take in this period is 400-700 meters. In addition, oxygen saturation and heart rate, resting fatigue and dyspnea levels will be evaluated with pulse oximetry before and after testing. Modified Borg Dyspnea and Fatigue Scales will be used to determine resting dyspnea and fatigue levels. | 8 weeks | |
Primary | Change of Endurance Shuttle Walking Test Distance from baseline to 8 weeks | Endurance Shuttle Walk test: This is a standardized field test for the assessment of endurance capacity. In the Endurance Shuttle Walk Test, the participant walks at a constant speed between cones spaced 10 m apart. The selected speed is 85% of the participant's maximum capacity measured in the shuttle walk test at increasing speed. Therefore, before this test, the patient should be given an increasing speed incremental shuttle walk test. | 8 weeks | |
Primary | Incremental Shuttle Walk Test | The incremental shuttle walk test (ISWT) is a field-based assessment of cardiorespiratory fitness and physical function. The ISWT is a performance-based assessment of exercise and functional capacity that measures walking distance in meters. It is a relatively brief and easy test to perform. The ISWT simulates a maximal cardiopulmonary test in a field setting and requires minimal equipment. Longer walking distances signify better performance. | 8 weeks | |
Secondary | Change of Fatigue Assessment Scale results from baseline to 8 weeks | Fatigue Assessment Scale: It was planned to use Fatigue Assessment Scale to evaluate subjective fatigue. The Fatigue Assessment Scale is a subjective fatigue questionnaire consisting of 10 items. It includes five-point Likert type options (1=Always-5=Never). Higher scores indicate greater levels of fatigue. | 8 weeks | |
Secondary | Change of Multidimensional Fatigue Inventory results from baseline to 8 weeks | Multidimensional Fatigue Inventory: It is used for the multidimensional evaluation of fatigue. It contains 20 questions containing different dimensions of fatigue. It consists of 5-point Likert-type questions. High scores indicate high fatigue. | 8 weeks | |
Secondary | Change of Blood Lactate Level from baseline to 8 weeks | Blood Lactate Level: Blood lactate level measurements, which are an objective outcome measure in the evaluation of fatigue, will be made, in the 1st week and 8th week, before the exercise, immediately after the exercise, at the 5th minute after the exercise, and at the 20th minute after the exercise. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04064242 -
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Terminated |
NCT00262132 -
Mycophenolate for Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT05415137 -
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT00001532 -
Role of Genetic Factors in the Development of Lung Disease
|
||
Completed |
NCT04318392 -
Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
|
||
Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
Completed |
NCT01587001 -
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
|
N/A | |
Recruiting |
NCT05890729 -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT02824419 -
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06205121 -
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
|
Phase 2 | |
Completed |
NCT02200146 -
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
|
Phase 3 | |
Terminated |
NCT01732211 -
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Enrolling by invitation |
NCT06169397 -
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 2 | |
Not yet recruiting |
NCT05247554 -
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
|
Phase 3 | |
Completed |
NCT03599414 -
CASPA: CArdiac Sarcoidosis in PApworth
|
||
Recruiting |
NCT02188017 -
Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)
|
Phase 4 | |
Recruiting |
NCT06113991 -
Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
|
||
Completed |
NCT01169038 -
Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
|
Phase 1 | |
Completed |
NCT00701207 -
Study of Nicotine Patches in Patients With Sarcoidosis
|
Early Phase 1 | |
Completed |
NCT03824392 -
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
|
Phase 1/Phase 2 |